6-K ·Filed Jul 8, 2026

TAK

TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001395064-26-000278
Notable filing: 6-K
Actionable Insight • Neutral

Routine compensation-related share issuance with no material financial impact. No trading action warranted. Monitor next quarterly results for any updates on employee incentive plan costs.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
TAK ▲ +6.63% at T+60d
NEUTRAL call ✓ call won +6.63% · α vs SPY +4.13% · entry $16.75 → $17.86
Entry anchored
Jul 7, 03:59 PM ET
via exchange tick
T+1d
-0.84%
call -0.84% · α -1.68%
$16.61
settled 3mo ago
T+5d
-2.15%
call -2.15% · α -3.01%
$16.39
settled 3mo ago
T+20d
-0.18%
call -0.18% · α -3.45%
$16.72
settled 8w ago
T+60d
+6.63%
call +6.63% · α +4.13%
$17.86
settled yesterday

Price Chart

Loading chart...

Executive Summary

Takeda completed the issuance of 16.88 million ordinary shares (including treasury shares) at 5,050 yen per share under its employee long-term incentive plan, with a slight reduction from the original plan due to forfeiture of rights. The company states the impact on full-year financials is immaterial. This is a routine administrative update with no material effect on the stock.

Key Facts

  • Issued 16,877,109 ordinary shares (10,780,950 new shares + 6,096,159 treasury shares) at 5,050 yen per share
  • Total value approximately 85.2 billion yen
  • Partial forfeiture of rights reduced the number of shares from originally planned 16,989,076
  • Company says immaterial impact on FY2027 financials

Financial Impact

Total value of shares issued and disposed is approximately 85.2 billion yen (about 16.88 million shares at 5,050 yen per share), but the company explicitly states the impact on full-year financials is immaterial

dilutionshare count

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
68% bullish (19 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001395064-26-000278
Document: 0001395064-26-000278-index-headers.html0001395064-26-000278
Document: 0001395064-26-000278-index.html0001395064-26-000278
Document: 0001395064-26-000278.txt0001395064-26-000278
13 reports for TAK
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for TAK — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$18.60 $18.89▲ +1.56%▲ +1.45%$17.86 (−3.98%)
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.18 $18.03▼ −0.83%▼ −1.30%$17.86 (−1.76%)
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.34 $18.23▼ −0.60%▼ −0.21%$17.86 (−2.62%)
Aug 14, 2026
7w ago
Court Ruling
NEUTRAL ★ 4/10
$17.63 $18.18▲ +3.12%▲ +4.49%$17.86 (+1.30%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$17.39 $18.13▲ +4.26%▲ +6.22%$17.86 (+2.70%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$17.39 $18.13▲ +4.26%▲ +6.22%$17.86 (+2.70%)
Jul 9, 2026
12w ago
6-K
NEUTRAL ★ 2/10
$16.61 $16.73▲ +0.72%▲ +0.85%$17.86 (+7.53%)
Jul 8, 2026
12w ago
6-K
NEUTRAL ★ 2/10
$16.75 $16.39▼ −2.15%▼ −3.01%$17.86 (+6.63%)
Jul 6, 2026
12w ago
3
NEUTRAL ★ 2/10
$16.89 $16.56▼ −1.95%▼ −2.44%$17.86 (+5.74%)
Jun 29, 2026
13w ago
6-K
NEUTRAL ★ 2/10
$15.98 $16.89▲ +5.69%▲ +4.31%$17.86 (+11.76%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (64h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access